- Home
- PCRX vs ACEL Comparison
PCRX vs ACEL Comparison
Compare PCRX & ACEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCRX | ACEL |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 948.2M |
| IPO Year | 2010 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PCRX | ACEL |
|---|---|---|
| Price | $23.43 | $11.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $30.25 | $14.67 |
| AVG Volume (30 Days) | ★ 517.6K | 284.0K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | 46.34 |
| EPS | 0.07 | ★ 0.17 |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $6.78 | $7.07 |
| Revenue Next Year | $8.54 | $2.81 |
| P/E Ratio | $338.29 | ★ $71.00 |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $9.55 |
| 52 Week High | $27.64 | $13.31 |
Technical Indicators
Market Signals| Indicator | PCRX | ACEL |
|---|---|---|
| Relative Strength Index (RSI) | 48.10 | 53.37 |
| Support Level | $22.06 | $10.82 |
| Resistance Level | $24.20 | $12.57 |
| Average True Range (ATR) | 1.04 | 0.27 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 44.31 | 75.56 |
Price Performance
Historical ComparisonAbout PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About ACEL Accel Entertainment Inc.
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.